Liudmila Fedorova

Statistics

Publications

Citations

122

H-Index

Active since

2020

Affiliations

First Pavlov State Medical University of St. Petersburg(Current)

Apple (Israel)

Liudmila Fedorova is an author at First Pavlov State Medical University of St. Petersburg specializing in oncology, relapsed hodgkin lymphoma, and immunotherapy.

ORCID

Publications per year

2020–2021

Publications

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Kirill V. Lepik, Liudmila Fedorova, Elena Kondakova et al. · HemaSphere · 2020 · 36 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure

Kirill V. Lepik, N.B. Mikhailova, Elena Kondakova et al. · HemaSphere · 2020 · 26 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations

Artem Gusak, Liudmila Fedorova, Kirill V. Lepik et al. · Cancers · 2021 · 26 citations · Full text

Medicine, Immunology, Oncology +17

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

Liudmila Fedorova, Kirill V. Lepik, N. Mikhailova et al. · Annals of Hematology · 2021 · 20 citations

Medicine, Oncology, Pharmacotherapy +13

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma

Liudmila Fedorova, Kirill V. Lepik, Polina Kotselyabina et al. · International Journal of Clinical Oncology · 2021 · 14 citations · Full text

Medicine, Immunology, Oncology +14

1–5 of 5